Physician profile
Sarah Thayer
NPI 1033484498
$2,629.64
in general payments reported to CMS, 2019-2025
25 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $345 · 2021: $613 · 2022: $364 · 2023: $476 · 2024: $238 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $757.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $348.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $296.32 | 2019-2024 | Mounjaro, Emgality, Zepbound |
| Abbvie INC. | $241.16 | 2021-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $211.99 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $153.94 | 2019-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $71.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.01 | 2019-2022 | |
| Amarin Pharma, INC. | $54.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.73 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $51.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $34.89 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.27 | 2021-2022 | |
| Allergan, INC. | $28.05 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $27.90 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.84 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $25.44 | 2023 | Rexulti |
| Pfizer INC. | $25.18 | 2020-2025 | |
| Eisai INC. | $23.37 | 2020-2021 | |
| Philips North America LLC | $21.20 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Mylan Specialty L.P. | $18.21 | 2019 | |
| Sobi, INC | $17.38 | 2019 | |
| Kci USA, INC. | $16.76 | 2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Emd Serono, INC. | $14.71 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Thayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.